References
- Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology 2000;148:3–15.
- Love RC. Strategies for increasing treatment compliance: The role of long-acting antipsychotics. Am J Health-Syst Pharm 2002;59(Suppl 8):10–5.
- Kane JM, Aguglia E, Altamura AC, Gutierrez JLA, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55–66.
- Remington GJ, Adams ME. Depot neuroleptic therapy: Clinical considerations. Can J Psychiatry 1995;40(3 Suppl 1):5–9.
- Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–32.
- Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq Z, Saleh BT. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003;19:298–305.
- Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–35.
- Risperdal Consta TM. Product Monograph. Janssen Cilag; 2002.
- Marder SR, Hubbard JW, Van Putten T, Midha KK. Pharmaco-kinetics of long-acting injectable neuroleptic drugs: Clinical implications. Psychopharmacology 1989;98:433–9.
- Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Thera-peutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors. Ther Drug Monit 1999;21:105–15.
- Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985;10:315–33.
- Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227–63.